HER2 Positive Cancer Clinical Trials

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

267 sites for NCT04784715

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

144 sites for NCT05113251

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +3 more drugs

chemotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

577 sites for NCT04457596

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

357 sites for NCT04622319

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

261 sites for NCT04873362

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

534 sites for NCT04266249

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +6 more drugs

chemotherapy, +2 more types

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

116 sites for NCT04740918

ERBB2 Amplification, +7 more biomarkers

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

498 sites for NCT03199885

HER2 Positive

Breast Adenocarcinoma

atezolizumab, +4 more drugs

chemotherapy, +2 more types

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

78 sites for NCT02693535

AKT1 Mutation, +128 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +19 more conditions

abemaciclib, +23 more drugs

immunotherapy, +1 more type

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

17 sites for NCT05152147

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

73 sites for NCT04739761

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer